[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BioAge Labs, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641062","phase-2-a-phase-2-study-to-evaluate-the-pharmacodynamics-safety-and-tolerability-of-bge-102-in-participants-with-obesity-and-cardiovascular-risk-factors-100641062",false,"NCT07656727","A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors","A Phase 2, Randomized, Double-Blind, Dose-Range, Placebo-Controlled, 12-Week Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors","Key Inclusion Criteria:\n\n* Obese Male and Female adults with BMI 32-42 kg\u002Fm²\n* Elevated blood test for hsCRP consistent with chronic systemic inflammation\n* At least one cardiovascular risk factor or metabolic syndrome feature\n* Stable background therapies and willing to maintain stable diet\u002Fexercise habits during the study\n\nKey Exclusion Criteria:\n\n* Type 1 diabetes,\n* Uncontrolled Type 2 diabetes,\n* Uncontrolled hypertension and \u002For hyperlipidemia\n* Recent weight change of 5% or more,\n* Use of weight-loss medications\u002Fprograms\n* Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.\n* Clinically significant ECG abnormalities or arrhythmias\n* Use of prohibited medications (including GLP-1 therapies, immunosuppressants, chronic anti-inflammatory drugs, or moderate or strong CYP3A4 modulators)\n* Contraindications to MRI\n* Clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass \\[bariatric\\] surgery or restrictive bariatric surgery), or have an endoscopic and\u002For device-based therapy for obesity\n* Women who are pregnant or nursing","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.",[26],"Obesity and Cardiovascular Risk",[28,29,30,31,32,33],"Obesity","Cardiovascular","BGE-102","hsCRP","BioAge","NLRP3","RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":38},"2026-06-11",{"date":42,"type":20},"2026-12",{"name":44,"class":45},"BioAge Labs, Inc.","INDUSTRY",13,""]